RCKT Stock Tanks on Patient Death in Danon Disease Study

Rocket Pharmaceuticals (RCKT) shares plummeted 62.8% after announcing a patient death in its Phase II trial of RP-A501 gene therapy for Danon disease, leading to a voluntary dosing pause and an FDA clinical hold. The patient experienced an acute systemic infection, prompting a comprehensive root cause analysis and collaboration with regulatory bodies to ensure patient safety before restarting the study. Year-to-date, Rocket Pharmaceuticals' shares have declined 81.5%, significantly underperforming the industry's 5.8% decline, compounded by previous setbacks including an FDA complete response letter for its Kresladi treatment.

Analysis

Rocket Pharmaceuticals (RCKT) experienced a significant adverse event, with its shares plummeting 62.8% on Tuesday following the announcement of a patient death in its pivotal phase II study of RP-A501, an investigational gene therapy candidate for Danon disease. The company disclosed that the patient suffered an acute systemic infection, leading to a voluntary pause in further dosing and an FDA-imposed clinical hold on the study, which was initiated last week. RCKT is undertaking a comprehensive root cause analysis and collaborating with regulatory bodies to address safety concerns, a critical step given management's prior assertion that RP-A501 was the first gene therapy to demonstrate safety and efficacy in clinical studies for a cardiovascular condition. This event exacerbates RCKT's already challenged stock performance, which has seen an 81.5% year-to-date decline, starkly underperforming the industry's 5.8% decrease. The company's pipeline has faced prior setbacks, notably with Kresladi for severe leukocyte adhesion deficiency-I (LAD-I), which received an FDA complete response letter (CRL) in June due to Chemistry Manufacturing and Controls (CMC) deficiencies—the second such request for Kresladi—followed by a three-month extension of its BLA review in February 2024, with a complete BLA refiling anticipated in 2025. Despite these accumulating challenges, Rocket Pharmaceuticals currently holds a Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should exercise extreme caution regarding Rocket Pharmaceuticals, given the severe implications of the patient death in the RP-A501 trial, the resultant FDA clinical hold, and the substantial 62.8% single-day share price collapse.
• The company's history of regulatory hurdles, including the complete response letter and extended review period for its Kresladi candidate, raises material concerns about its overall pipeline execution capabilities and the potential for further delays or failures.
• Closely monitor disclosures related to the root cause analysis for the RP-A501 adverse event, any communications from the FDA concerning the lifting of the clinical hold, and progress updates on resolving the Kresladi CRL, as these factors will be pivotal in reassessing the investment thesis.